Abdom Radiol (NY)

1. LIU Y, Xu Z, Xia J, Guo L, et al
   An interpretable contrast-enhanced CT-based cross-attention transformer model for predicting progression-free survival in muscle-invasive bladder cancer: a multicenter study.
   Abdom Radiol (NY). 2026 Oct 22. doi: 10.1007/s00261-026-05837.
   

   >> Share

   
   

   
   Acta Radiol

2. ZEINALKHANI F, Kamali Hakim P, Sharifi A, Azizzadeh A, et al
   Age as a pre-operative predictor of uterine, bladder, and intestinal invasion in cervical cancer.
   Acta Radiol. 2026 Sep 16:2841851261486043. doi: 10.1177/02841851261486043.
   

   >> Share

   
   

   
   Adv Sci (Weinh)

3. HONG G, Jiang F, Xie Y, Huang X, et al
   Multitask Deep Learning Model for Predicting Lymph Node Metastasis and Disease-Free Survival From Cytology Images in Bladder Cancer: A Multicenter Study With Pan-Cytology Validation.
   Adv Sci (Weinh). 2026 Oct 21:e76577. doi: 10.1002/advs.76577.
   

   >> Share

   
   

   
   Ann Oncol

4. BEDKE J, Arkosy P, Nishiyama H, Mahammedi H, et al
   Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study.
   Ann Oncol. 2026 Oct 23:S0923-7534(26)06888-2. doi: 10.1016/j.annonc.2026.
   

   >> Share

   
   
5. SONPAVDE G, van der Heijden MS, Gupta S, Galsky MD, et al
   Neoadjuvant nivolumab plus gemcitabine-cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine-cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial.
   Ann Oncol. 2026 Dec 31:S0923-7534(26)06877-8. doi: 10.1016/j.annonc.2026.
   

   >> Share

   
   

   
   BJU Int

6. DEPALMA M, Rossi F, Ferro M, Bukavina L, et al
   Enfortumab vedotin plus pembrolizumab in cisplatin-eligible muscle-invasive bladder cancer: efficacy proven, duration unclear.
   BJU Int. 2026 Oct 21. doi: 10.1111/bju.70507.
   

   >> Share

   
   

   
   BJUI Compass

7. IBRAHIM Y, Ribeiro L, Heelan M, Spazzapam M, et al
   NEITHER study: NICE versus EAU inconsistent triage, expenses and reliability in non-high-risk non-muscle invasive bladder cancer surveillance.
   BJUI Compass. 2026;7:e70283.
   

   >> Share

   
   

   
   BMC Anesthesiol

8. SAYGILI Y, Kose HC, Kose SG, Akkaya OT, et al
   A prospective randomized controlled trial comparing subpectineal and interfascial obturator nerve block techniques in preventing adductor muscle spasm during transurethral resection of bladder tumors.
   BMC Anesthesiol. 2026;26:622.
   

   >> Share

   
   

   
   BMC Cancer

9. SAKAI R, Shimada H, Hata S, Yokoyama A, et al
   Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells.
   BMC Cancer. 2026;26:1283.
   

   >> Share

   
   

   
   BMC Urol

10. YAO Q, Niu H, Jiang H, Xu L, et al
    Guidewire-assisted en bloc resection of periorifice non-muscle-invasive bladder cancer: a retrospective case series.
    BMC Urol. 2026;26:252.
    

    >> Share

    
    
11. CHAKER K, Chaabouni A, Elleuch W, Khadhar A, et al
    Predicting acute kidney injury after radical cystectomy for muscle-invasive bladder cancer.
    BMC Urol. 2026;26:253.
    

    >> Share

    
    

    
    Cancer Cell Int

12. TSAI TF, Chang HC, Lin YY, Chen YC, et al
    Capsaicin enhances chemosensitivity and mitigates MMP11-driven aggressiveness in human bladder cancer.
    Cancer Cell Int. 2026;26:346.
    

    >> Share

    
    

    
    Cancer Commun (Lond)

13. WU L, Qiao X, Wang W, Qiu J, et al
    Metabolic Competition-Driven Antitumor Immunity of glpX-Deficient Engineered Salmonella via Glucose Deprivation and STING Activation in Bladder Cancer.
    Cancer Commun (Lond). 2026;46:0060.
    

    >> Share

    
    

    
    Cancer Metastasis Rev

14. XU DM, Li M, Lin H, Zhuang XY, et al
    Before the seeds arrive: pre-metastatic niche orchestration in bladder cancer.
    Cancer Metastasis Rev. 2026;45:79.
    

    >> Share

    
    

    
    Cell Death Differ

15. CHEN JY, Ke ZB, Lin B, Liu MX, et al
    The NEK8/ALYREF axis promotes cisplatin resistance in bladder cancer by stabilizing CDK18 mRNA to facilitate DNA damage repair.
    Cell Death Differ. 2026 Oct 19. doi: 10.1038/s41418-026-01883.
    

    >> Share

    
    

    
    Cell Death Dis

16. DU E, Wang W, Su Q, Huang W, et al
    NEK2-AURKA axis drives ubiquitin-dependent IFT88 degradation to suppress ciliogenesis and promote basal-type bladder cancer.
    Cell Death Dis. 2026;17:903.
    

    >> Share

    
    

    
    Cell Death Discov

17. YAO J, Wang W, Li D, Xu C, et al
    The novel biguanide derivative 4C synergizes with talazoparib by inducing ferroptosis via the SREBP1/FASN/ SLC7A11/GPX4 axis in bladder cancer.
    Cell Death Discov. 2026;12:423.
    

    >> Share

    
    

    
    Cent European J Urol

18. PAKOVSKI K, Markova M, Janchulev J, Ambardjieva M, et al
    FGFR3 mRNA expression in urothelial bladder cancer: Associations with tumor phenotype without prognostic impact.
    Cent European J Urol. 2026;79:295-302.
    

    >> Share

    
    
19. HRECHKO BO, Voylenko O, Vitruk I, Stakhovsky O, et al
    Cytoreductive cystectomy combined with chemotherapy versus chemotherapy alone in the treatment of metastatic bladder cancer: A retrospective comparative study.
    Cent European J Urol. 2026;79:233-242.
    

    >> Share

    
    

    
    Clin Nucl Med

20. MAN X, Dong C, Dong A, Song X, et al
    Intradiverticular Bladder Cancer Mimicking a Normal Urinary Bladder Diverticulum on FDG PET/CT.
    Clin Nucl Med. 2026 Oct 20. doi: 10.1097/RLU.0000000000006729.
    

    >> Share

    
    

    
    Clin Transl Oncol

21. VAZQUEZ-ESTEVEZ S, Lazaro-Quintela M, Perez-Fentes D, Esteban-Gonzalez E, et al
    Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'.
    Clin Transl Oncol. 2026;28:5031-5054.
    

    >> Share

    
    

    
    Comput Struct Biotechnol J

22. YIN Z, Ho JWK
    The Current Status and Evaluation of Artificial Intelligence in Bladder Cancer: Clinical Applications and Research.
    Comput Struct Biotechnol J. 2026;35:0197.
    

    >> Share

    
    

    
    Curr Urol Rep

23. HIJAZI M, Hanna J, Sykes J, Golombos D, et al
    Novel Imaging Techniques Prior to Surgical Management of Invasive Bladder Cancer: A Systematic Review.
    Curr Urol Rep. 2026;27:58.
    

    >> Share

    
    

    
    Eur J Histochem

24. CHEN S, Li X, Zhan P, Luo T, et al
    AFF3 regulates ferroptosis and malignant progression in bladder cancer cells via the NRF2/GPX4 signaling axis.
    Eur J Histochem. 2026;70.
    

    >> Share

    
    

    
    Eur Urol

25. HAYNE D, Spalding L, Hawks C, McCombie S, et al
    Validation of a Computational Histology Artificial Intelligence-based Biomarker for BCG Treatment in Non-muscle-invasive Bladder Cancer in the ANZUP 1301 Randomized Phase 3 Trial.
    Eur Urol. 2026 Oct 21:S0302-2838(26)02433-4. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    

    
    Eur Urol Oncol

26. PATEL SR, Rauf M, Geng Y, Hinojosa-Gonzalez D, et al
    Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Oncol. 2026 Oct 20:S2588-9311(26)00275.
    

    >> Share

    
    

    
    Eur Urol Open Sci

27. GABRIEL PE, Marcq G, Zhu A, Sfakianos JP, et al
    Circulating Plasma and Urine Tumor DNA in Non-muscle-invasive Bladder Cancer: A Promising Biomarker to Guide Therapeutic Intensification.
    Eur Urol Open Sci. 2026;92:71-74.
    

    >> Share

    
    

    
    Front Immunol

28. LI S, Chen H, Feng B
    Bioengineering strategies to enhance BCG immunotherapy against bladder cancer.
    Front Immunol. 2026;17:1888889.
    

    >> Share

    
    
29. YANG M, Guo Y, Shen YZ, Sun YL, et al
    Reprogramming innate immune memory in bladder cancer: the proposed bone marrow-bladder axis and next-generation BCG-based immunotherapies.
    Front Immunol. 2026;17:1945559.
    

    >> Share

    
    
30. JIANG M, Zhao D, Zhang L, Zhu D, et al
    Integrated analyses identify MAN1B1 as a candidate regulator of chemotherapeutic tolerance and immunosuppression in bladder cancer.
    Front Immunol. 2026;17:1958628.
    

    >> Share

    
    

    
    Front Oncol

31. YUAN F, Li X, Zhang J, Gao JY, et al
    Risk factors for recurrence after initial transurethral resection of bladder tumor in patients with non-muscle-invasive bladder cancer.
    Front Oncol. 2026;16:1861461.
    

    >> Share

    
    
32. SUN Z, Xie R, Pan J, Zhu Y, et al
    Population-specific molecular features and clinical significance of urinary tumor DNA mutations in Chinese patients with newly diagnosed non-muscle-invasive bladder cancer.
    Front Oncol. 2026;16:1914617.
    

    >> Share

    
    

    
    Genes Dis

33. HAN X, Xie L, Li Z, Hou Y, et al
    Echinocystic acid inhibits the growth of human bladder cancer cells by suppressing AKT1/GSKbeta/beta-Catenin signaling and synergizes with gemcitabine.
    Genes Dis. 2026;14:102148.
    

    >> Share

    
    

    
    IMetaOmics

34. XU H, Li Z, Yang L, Zheng J, et al
    Microbiome-urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation.
    IMetaOmics. 2026;3:e70081.
    

    >> Share

    
    
35. LIANG T, Xu W, Fang H, Fu L, et al
    Integrin alpha5beta1-mediated multicellular crosstalk in the tumor microenvironment drives bladder cancer progression and reveals targetable vulnerabilities.
    IMetaOmics. 2026;3:e70102.
    

    >> Share

    
    

    
    Immunotherapy

36. LIU S, Lu J, Lyu Z, Lu Z, et al
    Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling.
    Immunotherapy. 2026;18:1111-1125.
    

    >> Share

    
    

    
    Infect Agent Cancer

37. JIN Y, Jin Y, Cui Y
    Bladder cancer in Africa, 2010-2023: burden, geographic heterogeneity, demographic drivers, pandemic-era temporal changes, and projections to 2030.
    Infect Agent Cancer. 2026;21:69.
    

    >> Share

    
    

    
    Int J Biol Sci

38. ZHANG C, Wei W, Cao S, Li Z, et al
    Exon-6 truncated p53 Suppresses Innate Immune Responses to Facilitate Immune Evasion in Bladder Cancer.
    Int J Biol Sci. 2026;22:8251-8270.
    

    >> Share

    
    

    
    Int J Clin Oncol

39. MATHIS BJ, Nagumo Y, Kimura T, Ishikawa H, et al
    Patient-reported outcome sub-analysis of a phase 2 trial of bladder preservation therapy with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer.
    Int J Clin Oncol. 2026 Oct 22. doi: 10.1007/s10147-026-03226.
    

    >> Share

    
    

    
    Int J Urol

40. TOMIOKA S, Inoue S, Kawase R, Nagasaka Y, et al
    Changes in Treatment Patterns and Survival Outcomes Across Therapeutic Eras in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study.
    Int J Urol. 2026;33:e70679.
    

    >> Share

    
    
41. KATAYAMA S, Kawada T, Mori K, Iwatani K, et al
    Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma.
    Int J Urol. 2026;33:e70664.
    

    >> Share

    
    

    
    Int Urol Nephrol

42. GAO F, Chen X, Gao W, Cheng Q, et al
    Two-step enucleation combined with needle electrode: a modified TURBT technique to enhance detrusor muscle detection.
    Int Urol Nephrol. 2026;58:4739-4750.
    

    >> Share

    
    

    
    J Imaging Inform Med

43. ZHANG Z, Cao K, Li J, He Z, et al
    Federated Learning-Based Multi-Task Framework for Privacy-Preserving Diagnosis of Muscle Invasion in Bladder Cancer.
    J Imaging Inform Med. 2026 Oct 22. doi: 10.1007/s10278-026-02429.
    

    >> Share

    
    

    
    J Med Chem

44. REN Y, Liu T, Hou X, Yao Y, et al
    Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma.
    J Med Chem. 2026;69:24388-24399.
    

    >> Share

    
    

    
    JAMA Netw Open

45. SU ZT, Garman TS, Rivera Lopez CA, Talwar R, et al
    Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer.
    JAMA Netw Open. 2026;9:e2640370.
    

    >> Share

    
    

    
    Lab Invest

46. ZHAO T, Nawrocki C, Xiong L, Nieman LT, et al
    Spatial Transcriptomics of Micropapillary, Plasmacytoid, and Sarcomatoid Urothelial Carcinoma Reveals Distinct Molecular Landscapes.
    Lab Invest. 2026;106:106160.
    

    >> Share

    
    

    
    Lancet Oncol

47. ITO A, Arai Y, Kakehi Y, Yokoyama M, et al
    Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2026;27:973-982.
    

    >> Share

    
    

    
    Med Oncol

48. ISMAIL Y, Kamal A, Aboulkassem H, Ashour MG, et al
    Bladder preservation is still feasible in the rare aggressive small cell carcinoma subtype.
    Med Oncol. 2026;43:339.
    

    >> Share

    
    
49. HE X, Zhang H, Zhang Y, Wu J, et al
    MG53 suppresses the progression of bladder cancer through E3 ubiquitin ligase-mediated degradation of AMPKalpha.
    Med Oncol. 2026;43:337.
    

    >> Share

    
    

    
    Medicine (Baltimore)

50. MA Y, Zhang Z, Tang L, Li Q, et al
    Development and validation of a ferroptosis and metabolic reprogramming gene signature for risk stratification in bladder urothelial carcinoma: A retrospective multicohort study.
    Medicine (Baltimore). 2026;105:e51078.
    

    >> Share

    
    

    
    Mol Cancer Res

51. SHAMSEDDINE A, Abbas N, Eichholz J, Chatila WK, et al
    Mutational Signatures and Hypermutation Phenotypes Define Bladder Cancers Arising in Waterpipe and Cigarette Smokers.
    Mol Cancer Res. 2026 Oct 20. doi: 10.1158/1541-7786.MCR-26-0157.
    

    >> Share

    
    

    
    Oncogene

52. HE W, Chen Q, Wang Z, Wang M, et al
    Single?cell multi?omics analysis reveals TGF-beta1-RUNX2-mediated matCAF differentiation and its role in remodeling the lymph node metastatic microenvironment in bladder cancer.
    Oncogene. 2026 Oct 23. doi: 10.1038/s41388-026-04022.
    

    >> Share

    
    

    
    Pathol Oncol Res

53. ALKAN GV, Dogan K, Turk Alkan M, Onder E, et al
    Prognosis and tumor grading in bladder urothelial carcinomas with intratumoral grade heterogeneity.
    Pathol Oncol Res. 2026;32:1612553.
    

    >> Share

    
    

    
    Photodiagnosis Photodyn Ther

54. FUKUHARA H, Shigehisa R, Yamamoto S, Fukata S, et al
    Comparison of oral 5-aminolevulinic acid-induced hypotension between general and spinal anesthesia during photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer.
    Photodiagnosis Photodyn Ther. 2026 Oct 22:105685.
    

    >> Share

    
    

    
    Radiother Oncol

55. VICKERS AJ, McSweeney DM, Choudhury A, Weaver J, et al
    DAG-informed analysis of muscle characteristics and overall survival in patients receiving radical treatment for bladder cancer.
    Radiother Oncol. 2026 Oct 21:111831. doi: 10.1016/j.radonc.2026.111831.
    

    >> Share

    
    

    
    Retina

56. MUELLER NM, Christensen CA, Mullane EM, Iacob CE, et al
    METASTATIC UROTHELIAL CARCINOMA OF THE BLADDER TO THE RETINA: A CLINICOPATHOLOGIC CORRELATION AND REVIEW OF THE LITERATURE.
    Retina. 2026;46:2076-2080.
    

    >> Share

    
    

    
    SLAS Technol

57. LI Y, Zuo L, Dong X, Sun R, et al
    NU-1025 modulates immunogenic cell death in bladder cancer: A multi-omics insight.
    SLAS Technol. 2026;43:100476.
    

    >> Share

    
    

    
    Support Care Cancer

58. BULKLEY JE, O'Keeffe-Rosetti M, Leo MC, Gilbert SM, et al
    Recovery after cystectomy and urinary diversion: patient experiences and challenges.
    Support Care Cancer. 2026;34:1113.
    

    >> Share

    
    

    
    Transl Oncol

59. WANG Y, Zhang S, Luo X, Wang Z, et al
    Integrative single-cell and computational pathology analyses reveal a C11orf24-associated stem-like epithelial population linked to tumor microenvironment remodeling and immune evasion in bladder cancer.
    Transl Oncol. 2026;74:103082.
    

    >> Share

    
    

    
    Urol Int

60. JOJIMA K, Minato A, Tsubonuma Y, Mizushima Y, et al
    Patient-reported outcome-informed individualized dose and schedule modification of enfortumab vedotin plus pembrolizumab in a nonagenarian patient with metastatic bladder cancer: a case report.
    Urol Int. 2026 Oct 21:1. doi: 10.1159.
    

    >> Share

    
    

    
    Urol Pract

61. DITONNO F, Veccia A, Musso G, Derweesh IH, et al
    Metachronous Contralateral Recurrence in Upper Tract Urothelial Carcinoma: A Multi-Institutional Competing-Risks Analysis From the ROBUUST 3.0 Registry.
    Urol Pract. 2026;13:623-632.
    

    >> Share

    
    
62. ABOU CHAKRA M, Myers AA, Duquesne I, Mott SL, et al
    Timing of FDA-Defined Adequate BCG Therapy and Oncologic Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer.
    Urol Pract. 2026 Oct 23:101097UPJ0000000000001109.
    

    >> Share

    
    

    
    Urologia

63. YADAV S, Madhavan K, Yadav A, Khurana U, et al
    A prospective cohort study to assess the diagnostic accuracy of VI-RADS score in a tertiary center in central India.
    Urologia. 2026;93:682-687.
    

    >> Share

    
    
64. CILLI M, Onol SY
    Comparison of complications in our extraperitoneal radical cystoprostatectomy with orthotopic urinary diversion cases and the intraperitoneal approach reported in the literature.
    Urologia. 2026;93:674-681.
    

    >> Share

    
    

    
    World J Urol

65. ALBERS LF, van Gennep EJ, van der Heijden MS, Pos FJ, et al
    Clinical response outweighs baseline nodal stage in treatment selection and survival of clinically node-positive bladder cancer.
    World J Urol. 2026;44:759.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share